Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Work In Process: 2021-2024

  • RedHill Biopharma's Work In Process rose 32.19% to $308,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $308,000, marking a year-over-year increase of 32.19%. This contributed to the annual value of $308,000 for FY2024, which is 32.19% up from last year.
  • According to the latest figures from Q4 2024, RedHill Biopharma's Work In Process is $308,000, which was up 32.19% from $233,000 recorded in Q4 2023.
  • Over the past 5 years, RedHill Biopharma's Work In Process peaked at $5.2 million during Q4 2021, and registered a low of $233,000 during Q4 2023.
  • Its 3-year average for Work In Process is $975,333, with a median of $308,000 in 2024.
  • As far as peak fluctuations go, RedHill Biopharma's Work In Process crashed by 90.23% in 2023, and later surged by 32.19% in 2024.
  • Over the past 4 years, RedHill Biopharma's Work In Process (Quarterly) stood at $5.2 million in 2021, then slumped by 54.09% to $2.4 million in 2022, then plummeted by 90.23% to $233,000 in 2023, then soared by 32.19% to $308,000 in 2024.
  • Its Work In Process was $308,000 in Q4 2024, compared to $233,000 in Q4 2023 and $2.4 million in Q4 2022.